Where does NRSN stock trade?

NeuroSense Therapeutics Ltd. (NRSN) is listed on NASDAQ.

What sector and industry is NRSN in?

NeuroSense Therapeutics Ltd. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.

When did NeuroSense Therapeutics Ltd. go public?

NeuroSense Therapeutics Ltd. (NRSN) completed its IPO in 2021.

What are analysts saying about NRSN?

NeuroSense Therapeutics Ltd. has had 1 recent analyst action on file. The most recent action was from Maxim Group: Buy with a $700.00 price target on 2022-01-07. Recent price targets cluster around $700.00.

What companies are similar to NRSN?

Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare NRSN side-by-side with any of them on Quantisnow.

How can I track NRSN on Quantisnow?

Quantisnow aggregates NeuroSense Therapeutics Ltd.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow NRSN to receive live email and push alerts on every new disclosure.

NRSN

NASDAQ

NeuroSense Therapeutics Ltd.

SectorHealth CareIndustryBiotechnology: Pharmaceutical PreparationsIPO2021

$0.76+0.01 (+1.01%)

News25/Ratings1

Price$0.76-0.01 (-1.61%)

01:30 PM05:30 PM

News · 26 weeks43-67%

2025-12-142026-06-07

Mix3190d

Insider13(42%)
SEC Filings9(29%)
Other9(29%)

Latest news

25 items

7hSEC
SEC Form 6-K filed by NeuroSense Therapeutics Ltd.
6-K - NeuroSense Therapeutics Ltd. (0001875091) (Filer)
41dSEC
SEC Form 6-K filed by NeuroSense Therapeutics Ltd.
6-K - NeuroSense Therapeutics Ltd. (0001875091) (Filer)
41dPR
NeuroSense Announces Pricing of Insider-Led PIPE Financing
Financing led by CEO Alon Ben-Noon and CFO Or Eisenberg, alongside participation from an existing significant shareholderCAMBRIDGE, Mass., April 28, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today announced the entry into a definitive agreement with certain investors to purchase $600,000 of ordinary shares in a private placement. In connection with the offering, NeuroSense agreed to sell an aggregate of 750,000 ordinary shares at a price of $0.80 per share, representing a purchase price of 6.7% above the closing pricing of NeuroSense's ordinary
45dSEC
SEC Form 6-K filed by NeuroSense Therapeutics Ltd.
6-K - NeuroSense Therapeutics Ltd. (0001875091) (Filer)
63dSEC
SEC Form 6-K filed by NeuroSense Therapeutics Ltd.
6-K - NeuroSense Therapeutics Ltd. (0001875091) (Filer)
63dPR
NeuroSense Granted Brazilian Patent Covering PrimeC Composition
Patent Protection Through October 2042Follows prior patent grants in the U.S. and AustraliaFurther strengthens NeuroSense's global intellectual property portfolioCAMBRIDGE, Mass., April 6, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) ("NeuroSense" or the "Company"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today announced that the Brazilian Patent and Trademark Office (INPI) has granted Brazilian Patent No. BR 112024007727-6, entitled "Compositions Comprising Ciprofloxacin and Celecoxib." The granted Brazilian patent, following prior approval of the corresponding U.S. patent (12,097,185) and Australian
66dPR
NeuroSense Therapeutics Announces Receipt of Nasdaq Notifications Regarding Minimum Bid Price and Market Value Requirements
Notifications have no immediate effect on the listing or trading of the Company's securities on NasdaqNasdaq has provided the Company until September 29, 2026 to regain compliance with both requirementsThe Company is actively evaluating actions to regain compliance, with a clear focus on initiatives that are aligned with and supportive of long-term shareholder valueCAMBRIDGE, Mass., April 3, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) ("NeuroSense" or the "Company"), a late-stage clinical biotechnology company developing treatments for severe neurodegenerative diseases, today announced that it received two notification letters from the Listing Qualifications Department of
66dSEC
SEC Form 6-K filed by NeuroSense Therapeutics Ltd.
6-K - NeuroSense Therapeutics Ltd. (0001875091) (Filer)
68dINSIDER
SEC Form 4 filed by Eisenberg Or
4 - NeuroSense Therapeutics Ltd. (0001875091) (Issuer)
68dINSIDER
SEC Form 3 filed by new insider Eisenberg Or
3 - NeuroSense Therapeutics Ltd. (0001875091) (Issuer)
69dINSIDER
SEC Form 3 filed by new insider Mandil-Levin Revital
3 - NeuroSense Therapeutics Ltd. (0001875091) (Issuer)
69dSEC
SEC Form 6-K filed by NeuroSense Therapeutics Ltd.
6-K - NeuroSense Therapeutics Ltd. (0001875091) (Filer)
69dSEC
SEC Form 20-F filed by NeuroSense Therapeutics Ltd.
20-F - NeuroSense Therapeutics Ltd. (0001875091) (Filer)
69dPR
NeuroSense Therapeutics Reports Year End 2025 Financial Results and Provides Business Update
2025 marked transition of PrimeC into a late-stage clinical asset with FDA-cleared Phase 3 program in ALSStatistically significant survival benefit demonstrated, including 65% reduction in risk of death and >14-month median survival advantageResults published in JAMA Neurology, providing high-level peer-reviewed validation of clinical and biological activityAdvancing toward key regulatory milestones with planned pre-NDS meeting in Canada and near-term Alzheimer's readoutCAMBRIDGE, Mass., March 31, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) ("NeuroSense" or the "Company"), a late-stage clinical biotechnology company developing treatments for severe neurodegenerative disea
69dINSIDER
SEC Form 3 filed by new insider Russek-Blum Niva
3 - NeuroSense Therapeutics Ltd. (0001875091) (Issuer)
69dINSIDER
SEC Form 4 filed by Russek-Blum Niva
4 - NeuroSense Therapeutics Ltd. (0001875091) (Issuer)
70dINSIDER
SEC Form 3 filed by new insider Ben-Noon Alon
3 - NeuroSense Therapeutics Ltd. (0001875091) (Issuer)
70dINSIDER
SEC Form 4 filed by Binder Hagit
4 - NeuroSense Therapeutics Ltd. (0001875091) (Issuer)
76dSEC
SEC Form 6-K filed by NeuroSense Therapeutics Ltd.
6-K - NeuroSense Therapeutics Ltd. (0001875091) (Filer)
76dPR
NeuroSense Advances Toward Key Regulatory Milestones with Strengthened Data Package and Near-Term Alzheimer's Readout
CAMBRIDGE, Mass., March 24, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) ("NeuroSense"), a late-stage clinical biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases, today provided an update on key regulatory and clinical milestones for its lead asset, PrimeC. Health Canada Pre-NDS Meeting A pre-New Drug Submission (pre-NDS) meeting with Health Canada has been rescheduled to May 2026.The decision was made to allow for the inclusion of additional emerging clinical, biomarker and survival data and analyses in the briefing package, which the Company believes will meaningfully strengthen the scientific and clinical foundation
82dINSIDER
SEC Form 3 filed by new insider Pellizzari Christine A
3 - NeuroSense Therapeutics Ltd. (0001875091) (Issuer)
82dINSIDER
SEC Form 3 filed by new insider Golan Roy
3 - NeuroSense Therapeutics Ltd. (0001875091) (Issuer)
82dINSIDER
SEC Form 3 filed by new insider Leuchtenberger Mark
3 - NeuroSense Therapeutics Ltd. (0001875091) (Issuer)
82dINSIDER
SEC Form 3 filed by new insider Binder Hagit
3 - NeuroSense Therapeutics Ltd. (0001875091) (Issuer)
82dINSIDER
SEC Form 3 filed by new insider Tracik Ferenc
3 - NeuroSense Therapeutics Ltd. (0001875091) (Issuer)

NRSN FAQ

6 questions

Where does NRSN stock trade?
NeuroSense Therapeutics Ltd. (NRSN) is listed on NASDAQ.
What sector and industry is NRSN in?
NeuroSense Therapeutics Ltd. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.
When did NeuroSense Therapeutics Ltd. go public?
NeuroSense Therapeutics Ltd. (NRSN) completed its IPO in 2021.
What are analysts saying about NRSN?
NeuroSense Therapeutics Ltd. has had 1 recent analyst action on file. The most recent action was from Maxim Group: Buy with a $700.00 price target on 2022-01-07. Recent price targets cluster around $700.00.
What companies are similar to NRSN?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare NRSN side-by-side with any of them on Quantisnow.
How can I track NRSN on Quantisnow?
Quantisnow aggregates NeuroSense Therapeutics Ltd.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow NRSN to receive live email and push alerts on every new disclosure.